| |
HER2+/HR+, n=28 (n=22)
|
HER2+/HR-, n=18 (n=16)
|
P-value
|
|---|
|
Response to neoadjuvant chemotherapy
| | | |
|
pCR (grade 3)
|
8 (8)
|
12 (11)
|
0.009 (0.034)
|
|
No pCR (grade 0–2)
|
14 (9)
|
3 (2)
| |
|
HER2 copy numbers
| | | |
|
≤ 2.0
|
6
|
2
|
0.368
|
|
> 2.0
|
22
|
16
| |
|
Wild-type HER2 mRNA
| | | |
|
< 400
|
16 (13)
|
7 (5)
|
0.05 (0.044)
|
|
≥ 400
|
7 (7)
|
11 (11)
| |
|
ΔHER2 mRNA
| | | |
|
< 4.5
|
16 (13)
|
3 (2)
|
<0.001 (0.001)
|
|
≥ 4.5
|
7 (7)
|
15 (14)
| |
|
Percentages of ΔHER2 mRNA
| | | |
|
< 2.4%
|
20 (18)
|
15 (14)
|
0.745 (0.813)
|
|
≥ 2.4%
|
3 (2)
|
3 (2)
| |
|
PI3KCA (exons 9 and 20)
| | | |
|
Wild-type
|
24 (19)
|
16 (14)
|
0.755 (0.418)
|
|
Mutated
|
4 (1)
|
2 (2)
| |
|
PI3KCA (exons 9 and 20)
| | | |
|
Wild-type + Normal + Loss + UPD
|
19 (18)
|
12 (12)
|
0.933 (0.611)
|
|
Mutated + Gain
|
9 (4)
|
6 (4)
| |
|
PTEN
| | | |
|
Normal + Gain + UPD
|
23 (20)
|
18 (16)
|
0.058 (0.215)
|
|
Loss
|
5 (2)
|
0 (0)
| |
|
INPP4B
| | | |
|
Normal + Gain + UPD
|
24 (20)
|
16 (14)
|
0.755 (0.735)
|
|
Loss
|
4 (2)
|
2 (2)
| |
|
PI3KCA , PTEN, INPP4B
| | | |
|
No aberrations*
|
15 (15)
|
10 (9)
|
0.895 (0.452)
|
|
Aberrations**
|
13 (7)
|
8 (7)
| |
|
DEK
| | | |
|
Normal
|
19 (17)
|
11 (11)
|
0.639 (0.556)
|
|
Gain
|
9 (5)
|
7 (5)
| |
|
FGFR1
| | | |
|
Normal + Loss + UPD
|
18 (15)
|
13 (12)
|
0.575 (0.871)
|
|
Gain
|
10 (7)
|
5 (4)
| |
|
CCND1
| | | |
|
Normal + Loss
|
16 (13)
|
9 (8)
|
0.635 (0.578)
|
|
Gain
|
12 (9)
|
9 (8)
| |
|
FOXA1
| | | |
|
Normal + UPD
|
20 (18)
|
13 (11)
|
0.953 (0.35)
|
|
Gain
|
8 (4)
|
5 (5)
| |
|
CDH3
| | | |
|
Normal + Loss + UPD
|
23 (19)
|
18 (16)
|
0.058 (0.124)
|
|
Gain
|
5 (3)
|
0 (0)
| |
|
BIRC5
| | | |
|
Normal + Loss + UPD
|
22 (17)
|
8 (6)
|
0.018 (0.013)
|
|
Gain
|
6 (5)
|
10 (10)
| |
|
MYBL2
| | | |
|
Normal + Loss
|
18 (15)
|
14 (13)
|
0.332 (0.366)
|
|
Gain
|
10 (7)
|
4 (3)
| |
|
AIB1
| | | |
|
Normal + Loss
|
19 (15)
|
14 (13)
|
0.466 (0.366)
|
|
Gain
|
9 (7)
|
4 (3)
| |
- Numbers in parentheses indicate patientsΔ numbers excluding 6 HER2+/HR+ and 2 HER2+/HR- patients whose tumors had HER2 copy numbers ≤ 2.0, and P-values calculated from the numbers in the parentheses.
- *No aberrations, wild-type and a normal copy of PIK3CA, a normal copy, gain or UPD of PTEN or INPP4B; **Aberrations, mutated and/or gain of PIK3CA, and loss of PTEN or INPP4B.
